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Abstract
Objectives: From a health care provider prospective, to assess the cost-effectiveness of four
Antiretroviral therapy (ART) regimens given in addition to voluntary counselling and testing (VCT)
for preventing mother-to-child transmission of HIV: a) Zidovudine (AZT); b) Nevirapine (NVP); c)
a combination of AZT for early antenatal attenders and NVP for late arrivals; and d) combined
administration of AZT and NVP and to assess the incremental cost-effectiveness of adding a second
VCT session in late pregnancy.
Design & Setting: We examine a hypothetical cohort of 100,000 pregnancies as a decision model.
Cost and outcome parameters are estimated as they would apply under Thai routine health service
conditions. Effectiveness probabilities are based on best available evidence, from systematic reviews
where possible. The main outcome is the number of cases of paediatric HIV averted.
Results: The combining administration of AZT and NVP is the most cost-effective drug option.
One VCT session with AZT+NVP averts 337 cases of infection at 556 USD per case averted, while
two VCT with the same drug regimen averts 16 additional cases at cost of 1,266 USD per infection
averted. The incremental cost-effectiveness ratio of moving from 1VCT, AZT+NVP to 2VCT,
AZT+NVP is 16,000 USD per additional averted case, which is much lower than the recommended
threshold value for HIV infection averted in Thailand. Multivariate uncertainty analysis supports the
findings, showing that at a threshold of 35,000 USD, 2VCT, AZT+NVP is preferable to other VCT
and drug strategies.
Conclusion: Interventions for preventing mother-to-child transmission of HIV are cost-effective.
Further costs and negative effects of drug resistance, are unlikely to outweigh the social benefits of
reduce transmission of HIV. This model suggests that the new drug regimen is a cost-effective
option in the Thai health system at currently accepted thresholds for adopting health technologies.
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Introduction
Thailand is one of the countries having most success fight-
ing the epidemic of HIV/AIDS infection [1,2]. Two ran-
domised clinical trials conducted in Thailand have
provided substantial impact on prevention of mother to
child transmission of HIV/AIDS (PMTCT). The first dem-
onstrated in 1999 that a short course of twice daily oral
Zidovudine (AZT) was safe, well-tolerated and, in the
absence of breast-feeding, lessened the risk for mother to
child HIV-1 transmission from 18.9% to 9.4% [3]. This
prompted the Thai Government to provide universal
access to a short course of AZT in 2000 [4,5].
The second trial recently reported that a combination of
AZT and a single dose of Nevirapine (NVP), administered
both to the mother during labour and to the newborn,
resulted in only two percent of children being born with
HIV [6]. On release of these results, the Thai National
Perinatal HIV Prevention programme incorporated this
new regimen into its policy [7].
By 2004 "the current practice" is 300 mg oral AZT twice a
day started at 28 week of gestation, a single dose of 200
mg NVP at onset of labour plus intra-labour 300 mg AZT
orally every three hours until delivery. Newborns receive a
single dose of NVP 6 mg after birth and AZT 2 mg per kg
every six hours for 7 days if the mother received 4 or more
weeks of AZT. The children born to mothers arriving late
in pregnancy or to mothers who received AZT for less than
4 weeks, are given a six-week AZT regimen [7].
The Thai PMTCT programme provides free services for
two rounds of Voluntary Counselling and Testing (VCT)
for all pregnant women, at first antenatal (ANC) visit and
at 28 weeks. The reason for the second VCT is to detect the
newly HIV infected during pregnancy. HIV infected preg-
nant women receive free antiretroviral drugs, breast milk
substitutes for 12 months and counselling with their part-
ner to test their newborn at 12 and 18 months. The Min-
istry of Public Health (MOPH) purchases drugs and
artificial milk in bulk and distributes it via its regional net-
works [8].
While modelling in a Sub-Saharan African setting [9],
revealed that a single NVP dose provided to both mother
and baby could be highly cost-effective in high sero-prev-
alence settings, the cost-effectiveness of NVP therapy in an
Asian setting where prevalence is lower is unknown.
On the other hand, several studies have raised concern
about the high rate of NVP resistance developing in moth-
ers treated with a single regimen [10-13]. The rate was as
high as 30–40% in South-Africa [14-16] and 17% in Thai-
land [17] and this would affect the choice of antiretroviral
therapy (HAART) if the mother needs to be treated later
on [18].
The purpose of this study is to appraise the cost-effective-
ness of the regimen introduced in 2004, compared (regi-
men D in table 1) with several alternatives: 1) the previous
Thai practice – a short course AZT regimen (regimen A); 2)
the cheapest regimen consisting of a single NVP dose (reg-
imen B); and 3) a mixed regimen of short course AZT for
ANC arrivals at 34 weeks of gestation, and NVP for late
arrivals beyond 34 weeks and for those who refuse the
AZT regimen (regimen C). The last option is designed to
maximise the effectiveness and minimise the problem of
drug resistance. Furthermore, the analysis assesses the
value of a second VCT round by comparing the cost-effec-
tiveness of one and two maternal VCT for each of the four
drugs options.
Design & Methods
Study model
We use a hypothetical cohort of 100,000 pregnancies as
the study model. The decision tree in Figure 1 presents a
flow of the programme options. Cost and outcome
parameters are based on Thai settings. The combination
of one and two VCT sessions and four antiretroviral ther-
apy (ART) regimens leads to eight case options being con-
sidered within the model. For simplicity's sake we assign
codes 1 and 2 for single and double VCT strategy, and A-
D for four drug regimens.
Cost analysis is conducted from the perspective of the
Ministry of Public Health (MOPH) as the Thai govern-
ment pays all costs for VCT, ART and substitute feeding.
We measure the programme outcomes as the net cost to
the public-sector payer, total number of cases of paediatric
HIV infection averted, and cost per paediatric HIV infec-
tion averted.
The cost-effectiveness of each intervention is calculated as
(IC+AC-HC)/IA, where IC are the programme interven-
tion costs, AC additional healthcare cost due to NVP
resistance, HC the lifetime health care cost of an HIV
infected infant (or cost offset), and IA the number of HIV
infections averted by the intervention. We converted all
cost and effectiveness at the present value (2003) with dis-
counting of 5%.
Input parameters (table 2)
For each parameter we determine base-case values. A
maternal HIV infection rate of 1.5% was reported by
national sentinel surveillance 2001 [19]. A prospective
mother-to-child study from 1992 to 1994 in Bangkok [20]
found that with a second VCT round during pregnancy an
additional 4.7% (95% CI 2.7% and 7.5%) HIV positive
mothers were detected who had become infected duringCost Effectiveness and Resource Allocation 2005, 3:7 http://www.resource-allocation.com/content/3/1/7
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pregnancy. In other word, we assume the second VCT
picks up 4.7% of the incidence cases.
In Thailand, all pregnant women have at least one ANC
visit during pregnancy [21]. As it takes two weeks to know
the maternal HIV status the 7.4% of pregnant women
arriving late for ANC are likely to receive ART later than 36
weeks compromising the optimal period for effective AZT
treatment of four weeks [8].
The risk of perinatal transmission without treatment is
18.9% [3] and with breast-feeding is assumed to be an
additional 12% [22]. Lallemant et al [6] report that the
odds ratio of transmitting the virus by regimen D versus
control (no prevention) is 0.23 (95% CI 0.05 to 0.41).
The effectiveness of other drug options is derived from a
Cochrane systematic review [23] indicating an odds ratio
compared to placebo of 0.46 (95% CI 0.35 to 0.60) for
regimen A and 0.51 (95%CI 0.33 to 0.79) for regimen B.
To estimate the risk of transmission among late arrivals
for ANC who get AZT treatment less than 4 weeks in regi-
men A, we apply an odds ratio of 1.40 (95% CI 0.82 to
2.38) found in a Thai study [24] comparing the risk of
transmission between a short (from 36 weeks onwards)
and long (from 28 weeks) maternal course of AZT. In the
absence of evidence of the efficacy of regimen D started
after 28 weeks but before 36 weeks of gestation, we
assume the same efficacy if treatment is started before 34
weeks, and the lower efficacy of regimen A for those start-
ing after 34 weeks.
In 13 provinces in the North of Thailand [8] 75% of
infected pregnant women accepted AZT treatment after
knowing their HIV status. A recent study found a higher
proportion (84%) of pregnant women accepted regimen
D [17]. We use the former figure as the base case scenario
for infected women who knew their HIV status before 36
week of gestation and accepted AZT treatment in regimens
A and C, and the latter for regimen D.
As we know that women make their first antenatal visit
late in pregnancy tend to report low education and socio-
economic status [25]. We, therefore, assume a lower pro-
portion of 65% of infected pregnant women who know
their HIV status after 36 weeks accept AZT in programmes
A and C, and 75% of those accept AZT and NVP in pro-
gramme D. For those who refuse AZT treatment for what-
ever reason, we assume 50% would accept the simpler
regimen of NVP in programme C.
For the regimen of single NVP, we propose 85% of
infected pregnant women who know their serologic status
before 36 weeks and 75% thereafter enroll in the pro-
gramme B. This enrollment rate is slightly higher than
with AZT as drug administration is simpler.
The study presents all prices in US$ (USD) at 2003 price
units. Costs of providing VCT, maternal and infant
antiretroviral treatment are derived from 160 MOPH hos-
pitals [8]. Briefly, data on the units of each category of
resources used and valued were gathered by mean of a
questionnaire sent to each hospital participating in the
Table 1: Protocol of four drug regimens for health economic evaluation in Thai HIV transmission cost-effectiveness model
Code Drug regimens Zidovudine (AZT) Nevirapine (NVP)
mother infant mother infant
A A short course AZT 
(practice in Thailand to 
2004)
Starting from 32–34 
week of gestation 
onward + intrapartum 
doses
From birth for 7 days (6 
weeks in the case of the 
mother receiving <4 
weeks AZT)
Not provided Not provided
B NVP alone (never 
adopted in the national 
policy)
Not provide Not provide Intrapartum single dose Single dose after delivery
C AZT or NVP (never 
adopted in the national 
policy)
Start at 32 but not latter 
than 34 weeks of 
gestations + intrapartum 
doses but not with NVP
From birth for 7 days (6 
weeks in the case of the 
mother receiving <4 
weeks AZT) – and given 
only the cases that 
mother received AZT
If mother know HIV 
status after 34 weeks 
then give single dose but 
not with AZT
Single dose after delivery 
if mother received NVP 
only
D AZT and NVP (current 
practice, commencing 
from 2004)
Starting from 28 week of 
gestation onward + 
intrapartum doses
From birth for 7 days (6 
weeks in the case of the 
mother receiving <4 
weeks AZT)
In trapartum single dose Single dose after deliveryCost Effectiveness and Resource Allocation 2005, 3:7 http://www.resource-allocation.com/content/3/1/7
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The decision tree used to model the prevention of HIV vertical transmission Figure 1
The decision tree used to model the prevention of HIV vertical transmission. (VCT = voluntary counseling and HIV 
testing, GA = gestational age).
HIV infected infant
Taking one out of four drug regimens
non HIV infected infant
HIV postive
1
HIV infected infant
Refuse treatment
non HIV infected infant
VCT at GA 32 weeks
HIV infected infant
HIV postive (seroconversion during pregnancy)
Single VCT
non HIV infected infant
HIV negative
HIV negative
Pregnant women HIV infected infant
1
Taking one out of four drug regimens 0
non HIV infected infant
HIV postive 0
1
HIV infected infant
Double VCT
Refuse treatment 0
non HIV infected infant
0
First VCT at first ANC visit HIV infected infant
Taking one out of four drug regimens
non HIV infected infant
HIV postive (seroconversion during pregnancy)
1
HIV infected infant
Refuse treatment
HIV negative Second VCT at GA 32 weeks
non HIV infected infant
HIV negativeCost Effectiveness and Resource Allocation 2005, 3:7 http://www.resource-allocation.com/content/3/1/7
Page 5 of 11
(page number not for citation purposes)
study. Intervention unit costs include recurrent labour
and non-labour expenditures but exclude capital
depreciation.
A study in Thailand found that 17.4% (95% CI 12.0% to
22.7%) of infected mothers who were treated with a single
dose NVP developed a strain of HIV resistant to the drug
[17]. Several studies report that the resistant virus sponta-
neously reverts to a wide-type genotype by one year
[14,26], meaning that the resistance would not have
altered effectiveness of prevention in further pregnancies.
Nevertheless, the concern is that those who were resistant
Table 2: Estimated base-case values and their confidential intervals (CI) for input parameters in the Thai HIV cost-effectiveness model
Parameters Point 
estimate
95%CI for 
sensitivity 
analysis
Parameter 
distribution
Data sources
Epidemiology
Maternal HIV infection rate 1.5% Ref.19
ANC after gestational age 34 weeks 7.4% 6.7–8.0% Beta Ref.8
Rate of perinatal HIV transmission 18.9% 13.2–24.4% Beta Ref.3
Rate of transmission via breastfeeding 12.0% 7.0–17.0%* Beta Ref.22
Percent of HIV infection detected by second VCT 4.7% 2.70–7.5% Beta Ref.20
Rate of HIV infected mothers who, treated with NVP, developed HIV 
resistance to NVP
17.4% 12.0–22.7% Beta Ref.17
Rate of HIV infected mothers who need to be treated AIDS within a 
year after delivery
33.9% 29.6–38.3% Beta Ref.28
Efficacy of Antiretrovial therapy
Odds of transmitting the virus when mother received AZT > = 4 
weeks versus placebo
0.46 0.35–0.60 Normal Ref.23
Odds of transmitting the virus when mother received AZT < 4 weeks 
versus receiving AZT > = 4 weeks
1.40 0.82–2.38 Normal Ref.24
Risk of transmitting the virus with NVP regimen versus placebo 0.51 0.33–0.79 Normal Ref. 23
Risk of transmitting the virus with AZT+NVP regimen versus receiving 
AZT > = 4 weeks
0.23 0.05–0.41 Normal Ref.6
Compliance to the Programme
Infected pregnant women who know their HIV status before or at 36 
week of gestation and accept AZT
75% 70–90% Beta Ref.8
Infected pregnant women who know their HIV status after 36 week of 
gestation and accept AZT
65% 55–90%* Beta Assumption (see text)
Infected pregnant women who know their HIV status before or at 36 
week of gestation, do not accept AZT but accept NVP
50% 30–70%* Beta Assumption (see text)
Infected pregnant women who know their HIV status before or at 36 
week of gestation and accept NVP
85% 70–90%* Beta Assumption (see text)
Infected pregnant women who know their HIV status after 36 week of 
gestation and accept NVP
75% 70–90%* Beta Assumption (see text)
Infected pregnant women who know their HIV status before or at 36 
week of gestation and accept AZT+NVP
84% 80–90% Beta Ref.17
Infected pregnant women who know their HIV status after 36 week of 
gestation and accept AZT+NVP
75% 70–80%* Beta Assumption (see text)
Programme unit cost US$
2003
VCT for HIV negative pregnancy 2.69 1.57–7.79 Gramma Ref. 8
VCT for HIV positive pregnancy 7.10 3.82–14.54 Gramma Ref. 8
HIV testing for baby born by infected mother 5.61 3.18–11.65 Gramma Ref. 8
Cost of antepartum AZT (per weeks) 10.50 Thai Department of Health
Cost of intrapartum AZT 2.30 Thai Department of Health
Cost of infant AZT (per week) 17.20 Thai Department of Health
Cost of NPV for mother and infant 3.10 Price survey by authors
Breast milk substitutes (per 1 year) 175.90 Thai Department of Health
Incremental cost of switching from NNRTI-base treatment regimen to 
PI-based regimen
497 147–847 Gramma Ref.29
Public sector health expenditure
Life time pediatric HIV/AIDS treatment cost 1,680 1,340–2,015 Gramma Ref.30
Note that a range for sensitivity analysis derived from 95% CI of each parameter distribution except * that based on assumptionCost Effectiveness and Resource Allocation 2005, 3:7 http://www.resource-allocation.com/content/3/1/7
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and were then treated for AIDS following delivery would
have a much more difficult time controlling the virus
[13,18]. AIDS experts therefore recommend a more
expensive treatment regimen based on protease inhibitors
(PI) as a first line treatment for mothers with the NVP
resistant virus instead of the common and cheaper regi-
men, based on Non-Nucleoside Reverse Transcriptase
Inhibitors (NNRTI) [27]. A report from MOPH [28]
reveals 33.9% of infected mothers need treatment for
AIDS by a year after delivery and the incremental cost of
switching from the cheaper to the more expensive treat-
ment regimen is 497 USD (95% 147 USD to 847 USD)
assuming the incremental cost occurs only for the first
three years of the treatment [29].
Assuming 80% of lifetime paediatric HIV/AIDS treatment
cost is shouldered by the public sector, the lifetime medi-
cal care cost was estimated at 3,300 USD in 1997 (25 Baht
per 1 USD) [30]. Converting the 1997 figures to 2003 val-
ues using the general consumer price index, the public sec-
tor health expenditure for a case of paediatric AIDS is
1,680 USD (40 Baht per 1 USD). A range of 1,340–2,015
USD is proposed for sensitivity analysis. A clinical trial of
morbidity and mortality among breast fed and formula
fed infants of HIV-1-infected women in Kenya found a
similar overall mortality rate, incidence of diarrhea, pneu-
monia and other serious complications among the two
groups [31]. Therefore, we do not add costs of treatments
for excess diarrhoea and respiratory tract infections
among formula-fed infants.
Uncertainty analysis
To handle uncertainty in the model input parameters of
interest are ascribed a distribution that reflects the uncer-
tainty associated with their true value (table 2) and
entered in a probabilistic uncertainty analysis. For
example, the beta-distribution was the choice of distribu-
tion for probability parameters which were bounded zero-
one and the gamma distribution was modelled for unit
cost parameters [32].
The results from 1,000 calculations are presented in a CE
acceptability curve based on the concept of net-benefit
approach suggested by Stinnett and Mullahy [33] and
Briggs et al [34]. It shows the probability in the 1,000 iter-
ations of the model that any of the eight interventions is
the most cost-effective option given different willingness
to pay thresholds.
Results
The total programme cost, including costs of VCT, ART,
artificial milk and dealing with drug resistance, of option
1A is the cheapest; option 2D is the most expensive,
mainly due to the costs of second VCT and dealing with
the problem of drug resistance (Table 3 and Figure 2).
Options 1C and 2C have the lowest net programme cost
in comparison to the other drug regimens, while 1B and
2B are the most expensive alternatives, on account of the
higher cost of dealing with drug resistance and smaller
offset-cost.
The mixed regimen of AZT and NVP with 2 VCT sessions
(programme 2D) is the most effective strategy, averting
353 infections. Compared to programme 1D, the second
VCT session prevents a small number of 16 (353–337)
additional cases at the additional cost of 260,000 USDThe
least effective regimens are those based on AZT only, fol-
lowed by the single NVP regimens (1B and 2B) which pre-
vent 25 and 26 extra infections compared to the AZT only
regimens (1A and 2A).
Cost-effectiveness
Compared with no routine prophylactic ART, programme
1D is the most cost-effective regimen costing 556 USD to
avert one paediatric HIV infection. Option 2B is the least
Table 3: Costs, effectiveness and cost-effectiveness of 6 intervention options for the Thai HIV cost-effectiveness model, US$ 2003
Programme model 1A 1B 1C 1D 2A 2B 2C 2D
Programme cost 560,000 500,000 580,000 600,000 840,000 770,000 880,000 880,000
Incremental cost of switching NNRTI-base treatment to PI-
base treatment
160,000 30,000 150,000 160,000 30,000 160,000
Total programme cost 560,000 650,000 610,000 750,000 840,000 930,000 920,000 1,040,000
Life time treatment cost for pediatric HIV/AIDS 390,000 430,000 460,000 560,000 410,000 450,000 500,000 590,000
Net programme cost 170,000 220,000 160,000 190,000 430,000 480,000 410,000 450,000
Number of infections averted by the program 233 258 273 337 245 271 300 353
Cost-effectiveness ratio per averted infection 716 851 570 556 1,740 1,776 1,381 1,266
Note: numbers for programme costs are given to nearest 10,000 US$, 2003 price levelsCost Effectiveness and Resource Allocation 2005, 3:7 http://www.resource-allocation.com/content/3/1/7
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cost-effective regimen at more than three times the cost
per additional case prevented.
With relative little benefit gained from the second VCT, all
regimens with the single VCT strategy are more cost-effec-
tive than those with 2 VCT sessions.
Uncertainty analysis
We plotted acceptability curves using net-monetary bene-
fit approach for the choice of prevention strategy in figure
3. To explain this, we consider table 3 where the most
effective drug option is programme D. The incremental
cost of moving from 1D to 2D is 260,000 (450,000-
190,000) USD for 16 (353-337) additional infections
averted. In other words, the incremental cost-effectiveness
ratio of giving up the 1D regimen and adopting 2D is
16,000 USD per additional infection averted. In Figure 3
this incremental cost-effectiveness value is represented by
showing the line of 1D crossed the line of 2D at the ceiling
ratio of 15,000USD (they were not exactly the same value
since the first is a deterministic and the latter is a probabi-
listic value). If the decision maker would prefer a confi-
dence level greater than 95%, the threshold is 35,000 USD
per infection averted. Further studies would be needed to
improve the accuracy of the cost-effectiveness results. In
particular, better information on the proportion of
infected pregnancy detected by second VCT and the cost of
VCT would improve the model because these parameters
have the greatest bearing on uncertainty.
Having mentioned above that the rate of developing NVP
resistant virus among Thais was considerably lower than
Total programme cost component by voluntary counselling and HIV testing (VCT) and antiretroviral drug (ARV) options Figure 2
Total programme cost component by voluntary counselling and HIV testing (VCT) and antiretroviral drug (ARV) options.
-
200,000
400,000
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800,000
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1,200,000
1A 1B 1C 1D 2A 2B 2C 2D
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incremental cost of switching to PI- base ARV treatment regimen
cost of artificial milk
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of Sub-Saharan setting, we therefore tested the results
assuming a rate of developing HIV resistant to NVP as
high as in a Sub-Saharan setting (40%). Figure 4 illustrates
that the regimens that contains no NVP (A) or contains
less NVP (C) are dominant. Programme 2D is still to be
the preferable choice if the willingness to pay threshold
greater than 40,000 USD per HIV infection averted with
the statistical confidence level 95%. It is interesting to
note that 1A is a significantly dominant regimen at the
lowest threshold of zero willingness to pay, that is, where
a decision has been made that no further resources would
be attributed to healthcare.
Discussion
This study has presented an economic evaluation of a
comprehensive range of VCT and choices of drug regimen
for PMTCT in Thailand. We excluded a long course of AZT,
ACTG 076, in our assessment since it is relatively compli-
cated (given intravenous form of AZT to mother during
labour) and expensive, and may be difficult to adopt in
developing countries [35,36].
There are two major policy concerns in this study: whether
to recommend single or double VCT, and which of four
drug regimens is the most cost-effective investment per
infection averted in a setting with moderately high HIV
sero-prevalence in pregnancy. The assessment has proved
by both point estimate and multivariate uncertainty anal-
Acceptability curves using net-monetary benefit approach for the choice of prevention strategy Figure 3
Acceptability curves using net-monetary benefit approach for the choice of prevention strategy. The proportion 
of simulations in which a strategy has the highest net-benefit across all strategies among 1,000 replications of the model (sum of 
all probability at each maximum willingness to pay for one HIV infection averted or "ceiling ratio" equal 1).
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ysis that the programme D has a lower cost per paediatric
HIV infection averted than other alternatives.
For the choice of VCT, though, we found that 1VCT is less
costly than 2VCT. International experience with the
accepted cost-utility ratios suggests that cost per Life Year
Gained (LYG) or Quality Adjusted Life Year (QALY)
threshold is 3 × per capita GDP [37]. This application
would presently lead to a threshold value in Thailand of
between 21,000 USD per LYG or QALY or 407,000 USD
per paediatric HIV infection averted (assuming 19.4 LYG
per HIV infection averted and the current practice, pro-
gramme 2D, clearly represents value for money. Thus, our
evidence supports the new policy of the Thai National
Perinatal HIV Prevention programme having introduced
programme 2D as a national regimen for PMTCT.
This study is partly compatible with one conducted in
Mexico, another low HIV prevalence setting, [38]. Both
studies similarly identify that VCT has a major share of
total programme cost but also is essential to the efficacy of
the ART programme [39]. Minimisation of PMTCT cost in
low-prevalence setting should therefore focus on VCT
costs rather than drug cost. However, the result of this
study provides additional information that providing
artificial milk and dealing with the problem of drug resist-
ance also add a considerable cost.
Because the authors chose to explore costs and outcomes
of the PMTCT in particular context of Thai setting and use
only government perspective, applying these findings to
somewhere else or using other viewpoints should be done
with cautious. For example, the rate of accepting VCT in
Acceptability curves for the choice of prevention strategy at 40% of rate of HIV resistant to Nevirapine Figure 4
Acceptability curves for the choice of prevention strategy at 40% of rate of HIV resistant to Nevirapine.
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Thailand may be much higher than in other countries.
Also, the percentage of detecting HIV infection by the sec-
ond VCT used in this study is rather high. However, this
study offers a useful and comprehensive framework for
evaluation of the PMTCT, especially in developing coun-
tries where resources do not permit adequate
development of basic health need but shoulder a major
burden of HIV/AIDS.
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